Victoria Socha

DocwireNews

Washington, DC&mdash;Despite hemodialysis, patients with end-stage renal disease frequently experience predialysis hyperkalemia. The DIALIZE trial (NCT03303521), a phase 3b, randomized, double-blind, placebo-controlled trial, investigated the effect of sodium zirconium cyclosilicate (SZC) on predialysis serum potassium after the long interdialytic interval in dialysis patients with hyperkalemia.Steven Fishbane, MD, and colleagues conducted a post hoc analysis of data from DIALIZE to further examine the effect of SZC in hyperkalemic hemodialysis patients. Results were reported at Kidney Week 2019 in a presentation titled Sodium Zirconium Cyclosilicate (SZC) Improves Potassium Balance in Hyperkalemic Hemodialysis Patients: Results from the Phase 3b, Randomized, Placebo-Controlled DIALIZE Study.The DIALIZE trial included a total of 196 patients. Mean age was 58.1 years. The patients were randomized 1:1 to receive placebo (n=99) or SZC (n=97) 5 mg once daily starting dose on nondialysis days for 8 weeks: a 4-week SZC dose-titration phase [maximum, 15 g] to achieve target predialysis serum potassium 4.0 to 5.0 mmol/L and a 4-week stable-dose evaluation phase (SZC 0, 5, 10, or 15 g).Post hoc analyses of DIALIZE data included assessment of the number of visits where patients had serum potassium of 4&ndash;5 mmol/L and 3.5&ndash;5.5 mmol/L, as well as the maximum serum potassium during the evaluation phase. Cross tabulation of categorized change in potassium gradient from baseline to end of the evaluation phase was also assessed. The change in potassium gradient was defined as the difference between the predialysis serum potassium and dialysate potassium.Rapid lowering of serum potassium is permitted with a high serum potassium to dialysate potassium gradient at the start of hemodialysis. However, there can be an association between rapid serum potassium lowering and an increased risk of adverse events, such as cardiac arrhythmias and hospitalization.There was an association between SZC and more patients achieving serum potassium 4.0 to 5.0 mmol/L and being maintained as serum potassium 3.5 to 5.5 mmol/L versus placebo for one, two, three, and four visits. During the evaluation period, 56 patients in the placebo group had severe predialysis hyperkalemia (defined as serum potassium &ge;6 mmol/L) compared with only 14 in the SZC group.In the SZC group there was a shift in potassium gradient toward values below the reported higher risk threshold of 3 mmol/L: 30.6% of patients (n=11/36) moved from gradient 4&ndash;5 to 2&ndash;3 mmol/L and 55.6% (n=25/45) moved from 3&ndash;4 to 2&ndash;3 mmol/L.In conclusion, the researchers said, &ldquo;These findings suggest that treatment with SZC improves management and reduces the frequency of severe hyperkalemia in hemodialysis patients, which could potentially modify the risks associated with these factors.&rdquo;Source: Fishbane S, A-shurbaji A, Guzman N, et al. Sodium zirconium cyclosilicate (SZC) improves potassium balance in hyperkalemic hemodialysis patients: Results from the phase 3b, randomized, placebo-controlled DIALIZE study. Abstract of a presentation at the American Society of Nephrology Kidney Week 2019 (Abstract SA-OR061), November 9, 2019, Washington, DC.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

SZC Improves Potassium Balance in Hyperkalemic Dialysis Patients

ASN Kidney Week 2019

Despite hemodialysis, patients with end-stage renal disease frequently experience predialysis hyperkalemia.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe